Vivaldi Biosciences is a leading brand in the field of biosciences, focusing on the development of Delta NS1 vaccines for protection against viral respiratory diseases. With operations based in Colorado and Austria, their Research Innovation Center at Colorado State University and facility in Vienna provide a strong foundation for their research and development efforts. Vivaldi Biosciences boasts NGN Capital LLC as its lead investor, ensuring ongoing support for their innovative work.

The company's team of experts includes William Wick, a highly experienced CEO with an extensive background in investment and finance, and Thomas Muster, an accomplished virologist and entrepreneur with a wealth of knowledge in clinical vaccine development. Manfred Reiter, a senior vice president, possesses expertise in process development and manufacturing for human vaccines, while Amy Aspelund, vice president of Research & Development, brings strong leadership in gene cloning and sequencing. Carrie Brown, as vice president of Marketing & Communications, excels in corporate and investor communications.

The board of directors includes industry veterans such as Chairman John Costantino and Director Peter Johann, both with extensive experience in private equity, venture investing, and corporate development. Vivaldi Biosciences also benefits from the guidance of distinguished scientific advisors, including Peter Palese, Adolfo García-Sastre, and Elliott Kieff, who are internationally recognized for their research contributions in viral diseases and influenza. With their dedicated team and cutting-edge research, Vivaldi Biosciences is at the forefront of developing innovative vaccines to combat epidemic and pandemic respiratory diseases